Welcome!

News Feed Item

Anaphore Announces Name Change to RuiYi and New Additions to Shanghai Management Team

Moves underscore company focus on the discovery and development of novel biologic therapies in China

LA JOLLA, Calif. and SHANGHAI, Oct. 4, 2012 /PRNewswire/ -- Anaphore announced today that its corporate name has changed to RuiYi.  As part of the company's shift in strategy to the discovery and development of novel biologic therapies in China, including monoclonal antibodies that target G protein coupled receptors (GPCRs), RuiYi has also added three seasoned leaders to its management team in Shanghai.

"RuiYi's new direction will enable us to focus on building our capabilities in Shanghai as we collaborate with a number of innovative drug discovery and development companies to advance our technology," commented Paul Grayson, President and CEO of RuiYi.

New RuiYi Drug Discovery Team

RuiYi also announced today that it has added three key members to its management team to guide its GPCR drug discovery efforts.  Chris Song, Ph.D., joins as Director of Operations, Shouhua (Josh) Xiao, Ph.D., joins as Senior Director of Protein Technology and Lei Shi, Ph.D., joins as Director of Antibody Discovery.

"Chris, Josh and Lei are all exceptionally talented individuals with extensive industry experience that is essential as we continue building a truly outstanding biologics drug discovery company in Shanghai," commented Anke Kretz-Rommel, Ph.D., Vice President of Research and Development, RuiYi.

Dr. Song has more than 20 years of experience in biomedical research and business. Prior to joining RuiYi, he led marketing and sales efforts at OriGene Technologies for its China business initiative. Before OriGene, Chris was with Applied Biosystems China, driving business growth in the pharmaceutical/biotech sector. He also held the position of Business Development Manager at Novartis China, developing business strategy and leading licensing activities for the Oncology Business. Dr. Song received his M.B.A from Stephen M. Ross School of Business at the University of Michigan, his Ph.D. in Molecular Biology and Oncology from the University of Queensland, Australia and a B.Sc from Shandong University, China.

Dr. Xiao has worked in the biotech industry for over 14 years. Prior to joining RuiYi, he was Principal Scientist and led the biologics drug discovery efforts for Oncology at Amgen South San Francisco. Prior to Amgen, he managed the HTS/Molecular Pharmacology group at Tularik and previously worked at Millennium Pharmaceuticals. Dr. Xiao obtained his Ph.D. in Biochemistry from Louisiana State University and conducted his postdoctoral training with Dr. James Manley at Columbia University. He currently serves as Co-chair of the 2011-2012 EC Business & Career Development Committee of the Chinese-American BioPharmaceutical Society.

Dr. Shi joins RuiYi from Centyrex, an internal venture of Johnson & Johnson, where he was responsible for library technology development and lead generation in the area of immunology and oncology. Prior to Centyrex, Dr. Shi was a Senior Research Scientist at Centocor R&D of Johnson and Johnson, where he led a project on developing and validating large scale de novo antibody library technology on a novel phage display platform and was the leading author on the publication and patent on this effort.  Before his career in the biopharmaceutical industry, Dr. Shi conducted his postdoctoral research on innate immunology at Harvard Medical School and Massachusetts General Hospital. He obtained his Ph.D. in Molecular Biology from University of Illinois at Chicago and an Executive Master's degree in Technology Management from the University of Pennsylvania and the Wharton School of Business.

New RuiYi Corporate Headquarters

RuiYi is moving its corporate offices to new space in La Jolla, CA.  Effective November 15, 2012, RuiYi's California-based office will be at:  505 Coast Blvd South, La Jolla, CA 92037.

About RuiYi

RuiYi is focused on the discovery and development of novel biologic therapies in China, including monoclonal antibodies that target G protein coupled receptors (GPCRs).  RuiYi's executive management team has offices in La Jolla, California while all of RuiYi's discovery efforts are located in Shanghai, China.  RuiYi's research facility is located in the Zhangjiang Hi-Tech Park in Pudong Shanghai, China.

For more information please visit www.ruiyibio.com.

SOURCE RuiYi

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that CAST Software will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CAST was founded more than 25 years ago to make the invisible visible. Built around the idea that even the best analytics on the market still leave blind spots for technical teams looking to deliver better software and prevent outages, CAST provides the software intelligence that matter ...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous ar...
SYS-CON Events announced today that Daiya Industry will exhibit at the Japanese Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Ruby Development Inc. builds new services in short period of time and provides a continuous support of those services based on Ruby on Rails. For more information, please visit https://github.com/RubyDevInc.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
As businesses evolve, they need technology that is simple to help them succeed today and flexible enough to help them build for tomorrow. Chrome is fit for the workplace of the future — providing a secure, consistent user experience across a range of devices that can be used anywhere. In her session at 21st Cloud Expo, Vidya Nagarajan, a Senior Product Manager at Google, will take a look at various options as to how ChromeOS can be leveraged to interact with people on the devices, and formats th...
First generation hyperconverged solutions have taken the data center by storm, rapidly proliferating in pockets everywhere to provide further consolidation of floor space and workloads. These first generation solutions are not without challenges, however. In his session at 21st Cloud Expo, Wes Talbert, a Principal Architect and results-driven enterprise sales leader at NetApp, will discuss how the HCI solution of tomorrow will integrate with the public cloud to deliver a quality hybrid cloud e...
SYS-CON Events announced today that Yuasa System will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Yuasa System is introducing a multi-purpose endurance testing system for flexible displays, OLED devices, flexible substrates, flat cables, and films in smartphones, wearables, automobiles, and healthcare.
Is advanced scheduling in Kubernetes achievable? Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, will answer these questions and demonstrate techniques for implementing advanced scheduling. For example, using spot instances ...
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
The session is centered around the tracing of systems on cloud using technologies like ebpf. The goal is to talk about what this technology is all about and what purpose it serves. In his session at 21st Cloud Expo, Shashank Jain, Development Architect at SAP, will touch upon concepts of observability in the cloud and also some of the challenges we have. Generally most cloud-based monitoring tools capture details at a very granular level. To troubleshoot problems this might not be good enough.
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
SYS-CON Events announced today that Taica will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Taica manufacturers Alpha-GEL brand silicone components and materials, which maintain outstanding performance over a wide temperature range -40C to +200C. For more information, visit http://www.taica.co.jp/english/.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities – ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups. As a result, many firms employ new business models that place enormous impor...